Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Category Archives: Biosimilars
Guidance on Biosimilar Development Finalized by FDA
Bloomberg BNA posted an overview of the FDA’s guide on biosimilar development. Read the overview here.
Posted in Biosimilars
Leave a comment
Sandoz Launches First Biosimilar Drug in U.S.
A new chapter in the generics/innovator wars began Thursday as Sandoz, Novartis’ generics division launched its Neupogen biosimilar, Zarxio, in the U.S. at about a 15-30% discount from the price of Neupogen. While biosimilars have been marketed in Europe since 2006, Congress … Continue reading
Posted in Biosimilars
Tagged Biosimilars, biotechnology, biotechnology law, biotechnology news, intellectual property, ip, Novartis, Patent Law, patents, Sandoz, Warren Woessner, Zarxio
Leave a comment